Cerevel Therapeutics Holdings Inc (CERE) Company Profile & Statistics

Cerevel Therapeutics Holdings Inc
CERE
(Nasdaq - US)
Closed
34.43
+1.49 (+4.52%)
in:usd•As of: Jan 27, 2023 15:59 UTC -5
Open
33.27
High
34.69
Low
33.00

About Cerevel Therapeutics Holdings Inc

CEO

N. Anthony Coles

Headquarters

222 jacobs street, suite 200

cambridge, ma 02141, united states

Auditor

Ernst & Young LLP

Employees

200

Share Holders

Website

www.cerevel.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics Inc., formerly known as Acquisition Corp II, is headquartered in Boston.

Cerevel Therapeutics Holdings Inc Statistics

Valuation Measures

Market Capitalization ²	5.38B
Enterprise Value	5.47B
Enterprise Value/EBITDA (ttm)	-17.02
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	8.42
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-58.94%
Return on Invested Capital (ttm)	-53.93%
Return on Assets (ttm)	-42.40%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-321.32M
Net Income Avi to Common (ttm)	-317.76M
Diluted EPS (ttm)	-2.13

Share Statistics

Beta (5Y Monthly)	1.47
52-Week Change	44.85%
S&P500 52-Week Change	-8.15%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	156.32M
Dividend Yield	0.00%
Float ⁴	149.60M
% Held by Insiders	4.30%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	989.92M
Total Cash Per Share (mrq)	6.33
Total Debt (mrq)	335.01M
Total Debt/Equity (mrq)	55.52%
Current Ratio (mrq)	16.64%
Quick Ratio (mrq)	16.64%
Book Value Per Share (mrq)	3.86

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.35
Free Cash Flow (ytd)	-209.21M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Cerevel Therapeutics Holdings Inc

Trade With A Regulated Broker